SunTrust Banks Increases Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target to $155.00

Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective lifted by equities research analysts at SunTrust Banks from $135.00 to $155.00 in a note issued to investors on Friday, The Fly reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price target would indicate a potential upside of 51.23% from the company’s previous close.

A number of other research analysts also recently weighed in on ALXN. BMO Capital Markets dropped their target price on shares of Alexion Pharmaceuticals from $147.00 to $142.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. JPMorgan Chase & Co. dropped their price target on Alexion Pharmaceuticals from $168.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Oppenheimer reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Thursday. SVB Leerink increased their target price on Alexion Pharmaceuticals from $159.00 to $163.00 and gave the company an “outperform” rating in a report on Friday. Finally, TheStreet upgraded Alexion Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Tuesday, June 9th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $143.17.

Shares of NASDAQ:ALXN opened at $102.49 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.79 and a quick ratio of 3.82. Alexion Pharmaceuticals has a 1 year low of $72.67 and a 1 year high of $125.52. The company has a market cap of $22.63 billion, a P/E ratio of 9.36, a PEG ratio of 0.81 and a beta of 1.46. The stock’s fifty day moving average price is $110.49 and its 200-day moving average price is $102.94.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $3.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.32 by $0.79. The business had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.27 billion. Alexion Pharmaceuticals had a return on equity of 22.57% and a net margin of 15.28%. On average, sell-side analysts anticipate that Alexion Pharmaceuticals will post 9.95 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALXN. Comerica Bank increased its position in shares of Alexion Pharmaceuticals by 6.9% during the second quarter. Comerica Bank now owns 61,965 shares of the biopharmaceutical company’s stock worth $6,562,000 after purchasing an additional 3,992 shares in the last quarter. Cadence Bank NA purchased a new position in Alexion Pharmaceuticals during the 2nd quarter worth $281,000. Prudential PLC acquired a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $1,001,000. Fox Run Management L.L.C. purchased a new stake in Alexion Pharmaceuticals in the second quarter valued at about $400,000. Finally, Landsberg Bennett & Dubbaneh LLC raised its stake in Alexion Pharmaceuticals by 19.4% in the second quarter. Landsberg Bennett & Dubbaneh LLC now owns 4,080 shares of the biopharmaceutical company’s stock valued at $454,000 after buying an additional 662 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: How to find the components of the quick ratio

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.